Adocia
About
History
Management
Board of directors
Advisory board
Products and platforms
Pipeline
Technology Platforms
Careers
The « Adocians »
HR policy
Work environment
Join us
Partnering
Investors
Media
Contact
Contact us
Map and accessibility
Investors
Regulated information
Stock information
Corporate governance
General meeting
Media
Press releases
Media
EN
FR
Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin
Previous article
Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors
Next article
Adocia strengthens its diabetic foot ulcer patent portfolio
